Neuromyelitis Optica Market Size
Market Size in USD Bn
CAGR10.5%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 10.5% |
| Market Concentration | High |
| Major Players | Alexion Pharmaceuticals, AstraZeneca, Mitsubishi Chemical Group Corporation, Genetech / F.Hoffman-La Roche, Sanofi and Among Others |
please let us know !
Neuromyelitis Optica Market Analysis
The Neuromyelitis Optica Market is estimated to be valued at USD 1.14 Billion in 2025 and is expected to reach USD 2.29 Billion by 2032, growing at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2032. The increasing prevalence of neuromyelitis optica across the globe and rising demand for treating the condition is fueling the growth of the market. Moreover, the growing healthcare expenditure and increasing awareness about the neuromyelitis optica disease is also driving the demand for drugs and therapies used in the treatment.
The market is expected to witness positive growth over the forecast period owing to ongoing development of novel drugs and therapeutic strategies for neuromyelitis optica. Many pharmaceutical players are strongly focused on research and development of neuromyelitis optica treatment and this is further expected to create new opportunities. Additionally, increasing approval of drugs by regulatory bodies is also projected to support the market expansion through 2032.